ESC & iPSC News Volume 15.19 | May 20 2020

TOP STORY

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson’s Disease

Scientists report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous iPSCs, in a patient with idiopathic Parkinson’s disease. [N Engl J Med] Abstract

(Ranked by impact factor of the journal)

Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis

Using type 2 diabetes mellitus-patient-derived human iPSCs (hiPSCs), researchers found that in patients protected from cardiovascular disease, there was significantly elevated expression of an esterase, arylacetamide deacetylase, in vascular smooth muscle cells. [Cell Stem Cell] Abstract | Graphical Abstract

Unique Properties of a Subset of Human Pluripotent Stem Cells with High Capacity for Self-Renewal

Investigators showed that a subpopulation of archetypal human PSC enriched for high self-renewal capacity had distinct properties relative to the bulk of the population, including a cell cycle with a very low G1 fraction and a metabolomic profile that reflected a combination of oxidative phosphorylation and glycolysis. [Nat Commun] Full Article

The Mutational Impact of Culturing Human Pluripotent and Adult Stem Cells

Researchers used the mutation rates, spectra, and genomic distribution to model the accumulation of oncogenic mutations during typical in vitro expansion, manipulation or screening experiments using human stem cells. [Nat Commun] Full Article

Transient Inhibition of mTOR in Human Pluripotent Stem Cells Enables Robust Formation of Mouse-Human Chimeric Embryos

The authors found that a brief inhibition of mTOR with torin1 converted human PSCs from primed to naïve pluripotency. [Sci Adv] Full Article | Press Release

ZSCAN4⁺ Mouse Embryonic Stem Cells Have an Oxidative and Flexible Metabolic Profile

Investigators analyzed the Zscan4⁺ mouse stem cell metabolic phenotype associated with pluripotency maintenance and cell reprogramming. [EMBO Rep] Abstract | Graphical Abstract

Generation and Profiling of 2,135 Human ESC Lines for the Systematic Analyses of Cell States Perturbed by Inducing Single Transcription Factors

Researchers systematically examined the state changes of human pluripotent ESCs by the large-scale manipulation of single transcription factors. [Cell Rep] Full Article | Graphical Abstract

BCL-xL/BCL2L1 Is a Critical Anti-apoptotic Protein That Promotes the Survival of Differentiating Pancreatic Cells from Human Pluripotent Stem Cells

Investigators profiled the expression of BCL-2 family of proteins during pancreatic specification and observed an upregulation of BCL-xL, downregulation of BAK and corresponding downregulation of cleaved CASP3 representative of apoptosis. [Cell Death Dis] Full Article

Nucleosides Rescue Replication-Mediated Genome Instability of Human Pluripotent Stem Cells

The authors found that, compared with isogenic differentiated cells, PSCs exhibited evidence of considerably more DNA damage during the S phase of the cell cycle, apparently as a consequence of DNA replication stress marked by slower progression of DNA replication, activation of latent origins of replication, and collapse of replication forks. [Stem Cell Reports] Full Article | Press Release

Subscribe to one of our other 19 science newsletters such as Cell Therapy News & Mesenchymal Cell News.

Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells

Scientists discuss several recent studies demonstrating the feasibility of genetically modifying PSCs to escape immune attack and summarize the methods to evaluate hypoimmunogenicity. [iScience] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the ESC & iPSC research field.

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Fate Therapeutics, Inc. announced that the FDA has cleared the company’s Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. [Fate Therapeutics, Inc.] Press Release

Open-Access Science Funders Announce Price Transparency Rules for Publishers

Science journals will have to disclose the costs of publishing articles in order for them to be paid for by a coalition of research funders pushing for open access. [ScienceInsider] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Research Scientist – Stem Cells (Evotec SE)

NEW Fellowship Position – Genome Stem Cell Research (Center for Biologics Evaluation and Research)

NEW Postdoctoral Position – Human iPS Models (The Jackson Laboratory)

NEW Postdoctoral Fellow – Bioinformatics of Stem Cell Epigenetics (Albert Einstein College of Medicine)

PhD Candidate – Cardiovascular Diseases (University Medical Center Göttingen)

Senior Scientist – Human iPSC Gene Engineering (Empyrean Therapeutics Ltd)

Postdoctoral Fellow – ALS (Johns Hopkins University School of Medicine)

Faculty Position – Regenerative Medicine (Guangzhou Regenerative Medicine and Health Guangdong Laboratory)

Research Specialist – Stem Cells for Regenerative Medicine (University of Illinois at Chicago)

Postdoctoral Position – Human Pluripotent Stem Cells to Hepatobiliary Tissues (Johns Hopkins University School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in ESC & iPSC News? Click here to submit!

Comments or suggestions? Submit your feedback here.